Xtant Medical Holdings, Inc.
0.9000+0.03 (+3.45%)
Oct 29, 4:00:00 PM EDT · NYSE American · XTNT · USD
Key Stats
Market Cap
126.00MP/E (TTM)
-Basic EPS (TTM)
-0.04Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Xtant Medical swung to profitability in Q2 FY2025 ended June 30, 2025, posting $35.4M revenue—up 18% y/y—fueled by orthobiologics growth and $5.0M in license revenue, while gross margins climbed to 68.6% from 62.1% on better production efficiency and sales mix. Operating income hit $4.6M, reversing a $2.9M loss, with diluted EPS of $0.02 on 148.6M shares; YTD figures align consistently at $68.3M revenue (up 18% y/y) and $3.6M net income. Cash from operations reached $2.6M YTD, bolstering $7.0M cash reserves amid $12.0M line of credit draws and $22.3M term debt at 13.2% effective rate, with $5.0M revolver availability and covenant compliance. Post-quarter, Xtant inked deals to divest Coflex/CoFix assets for $17.5M (cash/note mix) and international hardware for $1.7M, eyeing Q3 close with $9.6M debt prepay. Revenue relies heavily on independent agents.
8-K
Xtant Q2 revenue surges 18%
Xtant Medical Holdings reported Q2 2025 revenue of $35.4 million, up 18% year-over-year, driven by orthobiologics and licensing gains, while gross margins expanded to 68.6% from 62.1% on lower costs and scale. The company swung to net income of $3.6 million and adjusted EBITDA of $6.9 million, generating $1.2 million in operating cash flow. It raised FY25 revenue guidance to $131-$135 million, signaling 11%-15% growth, yet the pending $19.2 million divestiture of non-core spinal implants and international units to Companion Spine could reshape its focus amid integration risks.
8-K
Annual meeting date set
Xtant Medical Holdings set November 7, 2025, as the date for its 2025 Annual Meeting of Stockholders, shifting more than 30 days from last year's event. This triggers a tight deadline: stockholder proposals for proxy inclusion must arrive by August 18, 2025, alongside advance notices for nominations under bylaws. Deadlines sharpen. Proxy materials roll out around September 15, 2025, with universal proxy rules applying for rival director solicitations.
8-K
Board refresh with new directors
Xtant Medical Holdings elected Abhinav Jain and Tyler Lipschultz to its Board on August 1, 2025, effective immediately, while Robert McNamara and Lori Mitchell-Keller resigned the same day amid an oral understanding with major shareholder Nantahala, which owns 49.1% of shares after acquiring 57 million in April. Jain, an analyst at Nantahala with financial expertise, joins the Compensation and Nominating Committees; Lipschultz, a 35-year veteran in orthopaedics and biologics, takes Audit and Compensation seats. These shifts refresh governance. No disagreements prompted the resignations.
8-K
Xtant sells spinal units for $19.2M
Xtant Medical signed deals on July 7, 2025, to sell its U.S. Coflex/CoFix spinal implant business for $17.5 million and its international hardware unit for $1.7 million to Companion Spine, netting $19.2 million total with $11 million cash and an $8.2 million note due December 31, 2025. Closings hinge on buyer financing and are slated for Q3 2025, enabling $9.6 million debt prepayment to MidCap while sharpening focus on core orthobiologics. Deals unlock liquidity, yet hinge on financing.
ATEC
Alphatec Holdings, Inc.
16.49-0.16
AXGN
AxoGen, Inc.
22.25+4.17
BSX
Boston Scientific Corporation
100.30-0.67
BVS
Bioventus Inc.
6.77-0.17
DYNT
Dynatronics Corp.
0.05+0.00
IART
Integra LifeSciences Holdings C
15.43-0.13
SIBN
SI-BONE, Inc.
15.26-0.53
SNN
Smith & Nephew SNATS, Inc.
35.78-0.76
TNON
Tenon Medical, Inc.
1.23+0.01
ZBH
Zimmer Biomet Holdings, Inc.
99.71-1.43